These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 28628677)

  • 1. Impact of a 31-gene Expression Profiling Test for Cutaneous Melanoma on Dermatologists' Clinical Management Decisions.
    Farberg AS; Glazer AM; White R; Rigel DS
    J Drugs Dermatol; 2017 May; 16(5):428-431. PubMed ID: 28628677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management Decisions Made by Physician Assistants and Nurse Practitioners in Cutaneous Malignant Melanoma Patients: Impact of a 31-Gene Expression Profile Test.
    Mirsky R; Prado G; Svoboda R; Glazer A; Rigel D
    J Drugs Dermatol; 2018 Nov; 17(11):1220-1223. PubMed ID: 30500144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors Affecting Dermatologists' Use of a 31-Gene Expression Profiling Test as an Adjunct for Predicting Metastatic Risk in Cutaneous Melanoma.
    Svoboda RM; Glazer AM; Farberg AS; Rigel DS
    J Drugs Dermatol; 2018 May; 17(5):544-547. PubMed ID: 29742186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Gene Expression Profile Testing on the Management of Squamous Cell Carcinoma by Dermatologists.
    Rebeca T; Giselle P; Litchman GH; Rigel DS
    J Drugs Dermatol; 2019 Oct; 18(10):980-984. PubMed ID: 31584775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Gene Expression Profiling on Decision-Making in Clinically Node Negative Melanoma Patients after Surgical Staging.
    Schuitevoerder D; Heath M; Cook RW; Covington KR; Fortino J; Leachman S; Vetto JT
    J Drugs Dermatol; 2018 Feb; 17(2):196-199. PubMed ID: 29462228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit.
    Grossman D; Okwundu N; Bartlett EK; Marchetti MA; Othus M; Coit DG; Hartman RI; Leachman SA; Berry EG; Korde L; Lee SJ; Bar-Eli M; Berwick M; Bowles T; Buchbinder EI; Burton EM; Chu EY; Curiel-Lewandrowski C; Curtis JA; Daud A; Deacon DC; Ferris LK; Gershenwald JE; Grossmann KF; Hu-Lieskovan S; Hyngstrom J; Jeter JM; Judson-Torres RL; Kendra KL; Kim CC; Kirkwood JM; Lawson DH; Leming PD; Long GV; Marghoob AA; Mehnert JM; Ming ME; Nelson KC; Polsky D; Scolyer RA; Smith EA; Sondak VK; Stark MS; Stein JA; Thompson JA; Thompson JF; Venna SS; Wei ML; Swetter SM
    JAMA Dermatol; 2020 Sep; 156(9):1004-1011. PubMed ID: 32725204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expanded evidence that the 31-gene expression profile test provides clinical utility for melanoma management in a multicenter study.
    Dillon LD; McPhee M; Davidson RS; Quick AP; Martin B; Covington KR; Zolochevska O; Cook RW; Vetto JT; Jarell AD; Fleming MD
    Curr Med Res Opin; 2022 Aug; 38(8):1267-1274. PubMed ID: 35081854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical impact of a 31-gene expression profile test for cutaneous melanoma in 156 prospectively and consecutively tested patients.
    Berger AC; Davidson RS; Poitras JK; Chabra I; Hope R; Brackeen A; Johnson CE; Maetzold DJ; Middlebrook B; Oelschlager KM; Cook RW; Monzon FA; Miller AR
    Curr Med Res Opin; 2016 Sep; 32(9):1599-604. PubMed ID: 27210115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of a prognostic 40-gene expression profiling test on clinical management decisions for high-risk cutaneous squamous cell carcinoma.
    Litchman GH; Fitzgerald AL; Kurley SJ; Cook RW; Rigel DS
    Curr Med Res Opin; 2020 Aug; 36(8):1295-1300. PubMed ID: 32372702
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical Utility of Dermoscopy and 31-Gene Expression Profiling by Dermatology Providers in Melanoma Management Care.
    Witkowski A; Lee C; Latour E; Vetto J; Ludzik J
    J Drugs Dermatol; 2022 Dec; 21(12):1347-1352. PubMed ID: 36468965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interim analysis of survival in a prospective, multi-center registry cohort of cutaneous melanoma tested with a prognostic 31-gene expression profile test.
    Hsueh EC; DeBloom JR; Lee J; Sussman JJ; Covington KR; Middlebrook B; Johnson C; Cook RW; Slingluff CL; McMasters KM
    J Hematol Oncol; 2017 Aug; 10(1):152. PubMed ID: 28851416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Attitudes of patients with cutaneous melanoma toward prognostic testing using the 31-gene expression profile test.
    Ahmed K; Siegel JJ; Morgan-Linnell SK; LiPira K
    Cancer Med; 2023 Jan; 12(2):2008-2015. PubMed ID: 35915969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Level of Evidence Review for a Gene Expression Profile Test for Cutaneous Melanoma.
    Dubin DP; Dinehart SM; Farberg AS
    Am J Clin Dermatol; 2019 Dec; 20(6):763-770. PubMed ID: 31359351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrating the melanoma 31-gene expression profile test with surgical oncology practice within national guideline and staging recommendations.
    Hyams DM; Covington KR; Johnson CE; Plasseraud KM; Cook RW
    Future Oncol; 2021 Feb; 17(5):517-527. PubMed ID: 33021104
    [No Abstract]   [Full Text] [Related]  

  • 15. Integration of a 31-Gene Expression Profile Into Clinical Decision-Making in the Treatment of Cutaneous Melanoma.
    Scott AM; Dale PS; Conforti A; Gibbs JN
    Am Surg; 2020 Nov; 86(11):1561-1564. PubMed ID: 32755379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimation of Prognosis in Invasive Cutaneous Melanoma: An Independent Study of the Accuracy of a Gene Expression Profile Test.
    Greenhaw BN; Zitelli JA; Brodland DG
    Dermatol Surg; 2018 Dec; 44(12):1494-1500. PubMed ID: 29994951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of a Noninvasive 2-Gene Molecular Assay for Cutaneous Melanoma and Effect on the Decision to Biopsy.
    Ferris LK; Jansen B; Ho J; Busam KJ; Gross K; Hansen DD; Alsobrook JP; Yao Z; Peck GL; Gerami P
    JAMA Dermatol; 2017 Jul; 153(7):675-680. PubMed ID: 28445578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance of Gene Expression Profile Tests for Prognosis in Patients With Localized Cutaneous Melanoma: A Systematic Review and Meta-analysis.
    Marchetti MA; Coit DG; Dusza SW; Yu A; McLean L; Hu Y; Nanda JK; Matsoukas K; Mancebo SE; Bartlett EK
    JAMA Dermatol; 2020 Sep; 156(9):953-962. PubMed ID: 32745161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing Genetic Expression Profiles in Melanoma Prognosis.
    Farberg AS; Glazer AM; Winkelmann RR; Rigel DS
    Dermatol Clin; 2017 Oct; 35(4):545-550. PubMed ID: 28886811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of patients at risk of metastasis using a prognostic 31-gene expression profile in subpopulations of melanoma patients with favorable outcomes by standard criteria.
    Gastman BR; Gerami P; Kurley SJ; Cook RW; Leachman S; Vetto JT
    J Am Acad Dermatol; 2019 Jan; 80(1):149-157.e4. PubMed ID: 30081113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.